HRP20141110T1 - Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo - Google Patents
Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo Download PDFInfo
- Publication number
- HRP20141110T1 HRP20141110T1 HRP20141110AT HRP20141110T HRP20141110T1 HR P20141110 T1 HRP20141110 T1 HR P20141110T1 HR P20141110A T HRP20141110A T HR P20141110AT HR P20141110 T HRP20141110 T HR P20141110T HR P20141110 T1 HRP20141110 T1 HR P20141110T1
- Authority
- HR
- Croatia
- Prior art keywords
- human
- integrin
- alpha9
- humanized anti
- variable region
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Humanizirano anti-humani-alfa9-integrin-protutijelo, naznačeno time, da obuhvaća varijabilno područje jakog lanca i varijabilno područje slabog lanca odabrane od sljedećih:
(a) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:11 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:17;
(b) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:13 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:17;
(c) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:15 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:9;
2. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje jakog lanca od protutijela je humani Igγ1.
3. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje slabog lanca od protutijela je humani Igκ.
4. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje jakog lanca od protutijela je humani Igγ1 a konstantno područje slabog lanca od protutijela je humani Igκ.
5. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:19 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:25.
6. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:21 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:25.
7. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:23 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:27.
8. Polinukleotid, naznačen time, da sadrži sekvencu koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1, i sekvencu koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1.
9. Vektor ekspresije, naznačen time, da sadrži polinukleotid koji obuhvaća sekvencu koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1, i polinukleotid koji obuhvaća sekvencu koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1.
10. Stanica domaćina, naznačena time, da je odabrana iz skupine koju čine sljedeće (a) i (b):
(a) stanica domaćina transformirana s vektorom ekspresije koji sadrži polinukleotid sa sekvencom koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1 kao i polinukleotid sa sekvencom koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1; i
(b) stanica domaćina transformirana s vektorom ekspresije koji sadrži polinukleotid sa sekvencom koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1 i s vektorom ekspresije koji sadrži polinukleotid sa sekvencom koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1.
11. Postupak proizvodnje humaniziranog anti-humani-alfa9-integrin-protutijela, naznačen time, da obuhvaća fazu kultiviranja stanice domaćina prema zahtjevu 10, kako bi se omogućila ekspresija humaniziranog anti-humani-alfa9-integrin-protutijela.
12. Humanizirano anti-humani-alfa9-integrin-protutijelo, naznačeno time, da se proizvodi pomoću postupka prema zahtjevu 11.
13. Farmaceutski pripravak za reumatoidni artritis, naznačen time, da obuhvaća humanizirano anti-humani-alfa9-integrin-protutijelo prema bilo kojem od zahtjeva 1 do 7 i 12.
14. Humanizirano anti-humani-alfa9-integrin-protutijelo prema bilo kojem od zahtjeva 1 do 7 i 12, naznačeno time, da se upotrebljava kao lijek.
15. Humanizirano anti-humani-alfa9-integrin-protutijelo prema bilo kojem od zahtjeva 1 do 7 i 12, naznačeno time, da se upotrebljava u postupku prevencije ili liječenja reumatoidnog artritisa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008004975 | 2008-01-11 | ||
| JP2008282496 | 2008-10-31 | ||
| PCT/JP2009/050187 WO2009088064A1 (ja) | 2008-01-11 | 2009-01-09 | 改良型ヒト化抗ヒトα９インテグリン抗体 |
| EP09700904.7A EP2243829B1 (en) | 2008-01-11 | 2009-01-09 | IMPROVED HUMANIZED ANTI-HUMAN alpha9-INTEGRIN ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141110T1 true HRP20141110T1 (hr) | 2015-01-16 |
Family
ID=40853174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141110AT HRP20141110T1 (hr) | 2008-01-11 | 2014-11-17 | Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8603476B2 (hr) |
| EP (2) | EP2243829B1 (hr) |
| JP (2) | JP5440179B2 (hr) |
| KR (1) | KR101634636B1 (hr) |
| CN (1) | CN101918549B (hr) |
| AU (1) | AU2009203369B2 (hr) |
| BR (1) | BRPI0905656B8 (hr) |
| CA (1) | CA2711882C (hr) |
| CY (1) | CY1115897T1 (hr) |
| DK (1) | DK2243829T3 (hr) |
| ES (1) | ES2519047T3 (hr) |
| HR (1) | HRP20141110T1 (hr) |
| IL (1) | IL206898A (hr) |
| MX (1) | MX2010007515A (hr) |
| PL (1) | PL2243829T3 (hr) |
| PT (1) | PT2243829E (hr) |
| RU (1) | RU2503720C2 (hr) |
| SI (1) | SI2243829T1 (hr) |
| TW (1) | TWI432453B (hr) |
| WO (2) | WO2009088064A1 (hr) |
| ZA (1) | ZA201004770B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2406285B1 (en) * | 2009-03-10 | 2016-03-09 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| SG194793A1 (en) * | 2011-05-06 | 2013-12-30 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| EP2766391A1 (en) * | 2011-10-13 | 2014-08-20 | NVIP Pty Ltd | Canine/feline cd20 binding epitope and compositions for binding thereto |
| JP2021008406A (ja) * | 2017-09-29 | 2021-01-28 | アステラス製薬株式会社 | 改良型ヒト化抗ヒトα９インテグリン抗体含有医薬組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6114143A (en) | 1993-03-11 | 2000-09-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-HIV monoclonal antibody |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| NZ528483A (en) | 2001-04-05 | 2008-03-28 | Astellas Pharma Inc | Anti-osteopontin antibody and use thereof |
| EP1431310A4 (en) * | 2001-09-25 | 2005-03-23 | Immuno Biological Lab Co Ltd | ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF |
| US20060241067A1 (en) * | 2002-06-25 | 2006-10-26 | Varner Judith A | Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| PT2322556E (pt) | 2004-09-03 | 2016-02-15 | Genentech Inc | Antagonistas humanizados anti-beta7 e suas utilizações |
| JP4871740B2 (ja) * | 2005-01-13 | 2012-02-08 | 株式会社ジーンテクノサイエンス | 抗α９インテグリン抗体とその用途 |
| CA2653661A1 (en) | 2006-05-31 | 2007-12-06 | Astellas Pharma Inc. | Humanized anti-human osteopontin antibody |
| JP4841326B2 (ja) | 2006-06-20 | 2011-12-21 | 三菱電機株式会社 | ホームネットワークシステム |
| KR101429783B1 (ko) * | 2006-07-12 | 2014-08-18 | 가부시키가이샤 진 테크노 사이언스 | 항 인간 α９ 인테그린 항체와 그 용도 |
| JP2008282496A (ja) | 2007-05-11 | 2008-11-20 | Konica Minolta Opto Inc | 光ピックアップ装置 |
| JP2007302676A (ja) * | 2007-05-29 | 2007-11-22 | Genentech Inc | ヒト化抗β７アンタゴニストおよびその使用 |
-
2009
- 2009-01-09 CN CN2009801019731A patent/CN101918549B/zh not_active Expired - Fee Related
- 2009-01-09 KR KR1020107017150A patent/KR101634636B1/ko active IP Right Grant
- 2009-01-09 MX MX2010007515A patent/MX2010007515A/es active IP Right Grant
- 2009-01-09 JP JP2009548961A patent/JP5440179B2/ja not_active Expired - Fee Related
- 2009-01-09 SI SI200931034T patent/SI2243829T1/sl unknown
- 2009-01-09 ES ES09700904.7T patent/ES2519047T3/es active Active
- 2009-01-09 DK DK09700904.7T patent/DK2243829T3/da active
- 2009-01-09 US US12/812,341 patent/US8603476B2/en active Active
- 2009-01-09 AU AU2009203369A patent/AU2009203369B2/en not_active Ceased
- 2009-01-09 TW TW098100558A patent/TWI432453B/zh not_active IP Right Cessation
- 2009-01-09 WO PCT/JP2009/050187 patent/WO2009088064A1/ja active Application Filing
- 2009-01-09 RU RU2010133550/10A patent/RU2503720C2/ru active
- 2009-01-09 PT PT97009047T patent/PT2243829E/pt unknown
- 2009-01-09 PL PL09700904T patent/PL2243829T3/pl unknown
- 2009-01-09 EP EP09700904.7A patent/EP2243829B1/en active Active
- 2009-01-09 CA CA2711882A patent/CA2711882C/en active Active
- 2009-01-09 EP EP09700866A patent/EP2239323A4/en not_active Withdrawn
- 2009-01-09 WO PCT/JP2009/050188 patent/WO2009088065A1/ja active Application Filing
- 2009-01-09 BR BRPI0905656A patent/BRPI0905656B8/pt not_active IP Right Cessation
- 2009-01-09 JP JP2009548962A patent/JPWO2009088065A1/ja not_active Abandoned
- 2009-07-09 US US12/812,368 patent/US20110014193A1/en not_active Abandoned
-
2010
- 2010-07-06 ZA ZA2010/04770A patent/ZA201004770B/en unknown
- 2010-07-08 IL IL206898A patent/IL206898A/en active IP Right Grant
-
2014
- 2014-11-12 CY CY20141100944T patent/CY1115897T1/el unknown
- 2014-11-17 HR HRP20141110AT patent/HRP20141110T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141110T1 (hr) | Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo | |
| HRP20140915T1 (hr) | Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo | |
| HRP20220081T1 (hr) | Bcma i cd3 bispecifična t stanica koja uključuje konstrukte protutijela | |
| HRP20201113T1 (hr) | Vežući proteini protiv lag-3 | |
| HRP20210372T1 (hr) | Anti-lag3 antitijela i antigen-vezujući fragmenti | |
| HRP20191865T1 (hr) | Novi heterodimerni proteini | |
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| HRP20200189T1 (hr) | Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20180155T1 (hr) | Novo protutijelo protiv ljudskog ngf | |
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| MY166282A (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses | |
| HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| RU2013140350A (ru) | Антитела против человеческого il33r и их применение | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| JP2016532457A5 (hr) | ||
| MX2013002379A (es) | Moleculas de union a vegf. |